116 related articles for article (PubMed ID: 17147697)
1. Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists.
Krause S; Schmoldt HU; Wentzel A; Ballmaier M; Friedrich K; Kolmar H
FEBS J; 2007 Jan; 274(1):86-95. PubMed ID: 17147697
[TBL] [Abstract][Full Text] [Related]
2. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
3. Peptide agonists of the thrombopoietin receptor.
Dower WJ; Cwirla SE; Balasubramanian P; Schatz PJ; Baccanari DP; Barrett RW
Stem Cells; 1998; 16 Suppl 2():21-9. PubMed ID: 11012174
[TBL] [Abstract][Full Text] [Related]
4. Microbodies.
Schmoldt HU; Daneschdar M; Kolmar H; Blind M
Methods Mol Biol; 2009; 535():361-72. PubMed ID: 19377985
[TBL] [Abstract][Full Text] [Related]
5. Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins.
Kolmar H
Curr Opin Pharmacol; 2009 Oct; 9(5):608-14. PubMed ID: 19523876
[TBL] [Abstract][Full Text] [Related]
6. Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins.
Kolmar H
FEBS J; 2008 Jun; 275(11):2684-90. PubMed ID: 18435757
[TBL] [Abstract][Full Text] [Related]
7. Regulation of cell differentiation by hNUDC via a Mpl-dependent mechanism in NIH 3T3 cells.
Zhang YP; Tang YS; Chen XS; Xu P
Exp Cell Res; 2007 Sep; 313(15):3210-21. PubMed ID: 17658515
[TBL] [Abstract][Full Text] [Related]
8. Engineered cystine knot miniproteins as potent inhibitors of human mast cell tryptase beta.
Sommerhoff CP; Avrutina O; Schmoldt HU; Gabrijelcic-Geiger D; Diederichsen U; Kolmar H
J Mol Biol; 2010 Jan; 395(1):167-75. PubMed ID: 19852971
[TBL] [Abstract][Full Text] [Related]
9. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.
Van Herrewege Y; Morellato L; Descours A; Aerts L; Michiels J; Heyndrickx L; Martin L; Vanham G
J Antimicrob Chemother; 2008 Apr; 61(4):818-26. PubMed ID: 18270220
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
Newland A
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
[TBL] [Abstract][Full Text] [Related]
11. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.
Cwirla SE; Balasubramanian P; Duffin DJ; Wagstrom CR; Gates CM; Singer SC; Davis AM; Tansik RL; Mattheakis LC; Boytos CM; Schatz PJ; Baccanari DP; Wrighton NC; Barrett RW; Dower WJ
Science; 1997 Jun; 276(5319):1696-9. PubMed ID: 9180079
[TBL] [Abstract][Full Text] [Related]
12. Potent agonists of a hematopoietic stem cell cytokine receptor, c-Mpl.
Tarasova A; Haylock DN; Meagher L; Be CL; White J; Nilsson SK; Andrade J; Cartledge K; Winkler DA
ChemMedChem; 2013 May; 8(5):763-71. PubMed ID: 23554275
[TBL] [Abstract][Full Text] [Related]
13. Secretion expression and activity assay of a novel fusion protein of thrombopoietin and interleukin-6 in Pichia pastoris.
Zhiyi H; Wenshan L; Wenze Z; Ning D; Chi Z; Kenan Y; Ping W; Qianqian W; Qing Z
J Biochem; 2007 Jul; 142(1):17-24. PubMed ID: 17517790
[TBL] [Abstract][Full Text] [Related]
14. Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor.
Yamane N; Tanaka Y; Ohyabu N; Yamane S; Maekawa K; Ishizaki J; Suzuki R; Itoh T; Takemoto H
Eur J Pharmacol; 2008 May; 586(1-3):44-51. PubMed ID: 18377892
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of thrombopoietin mimetic peptide GW395058 in BALB/c mice and New Zealand white rabbits: evaluation of the potential for thrombopoietin neutralizing antibody production in man.
de Serres M; Ellis B; Dillberger JE; Rudolph SK; Hutchins JT; Boytos CM; Weigl DL; DePrince RB
Stem Cells; 1999; 17(4):203-9. PubMed ID: 10437983
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL.
Nishino T; Miyaji K; Ishiwata N; Arai K; Yui M; Asai Y; Nakauchi H; Iwama A
Exp Hematol; 2009 Nov; 37(11):1364-1377.e4. PubMed ID: 19744539
[TBL] [Abstract][Full Text] [Related]
17. Engineered cystine-knot miniproteins for diagnostic applications.
Kolmar H
Expert Rev Mol Diagn; 2010 Apr; 10(3):361-8. PubMed ID: 20370592
[TBL] [Abstract][Full Text] [Related]
18. Mice rendered severely deficient in megakaryocytes through targeted gene deletion of the thrombopoietin receptor c-Mpl have a normal skeletal phenotype.
Perry MJ; Redding KA; Alexander WS; Tobias JH
Calcif Tissue Int; 2007 Sep; 81(3):224-31. PubMed ID: 17674074
[TBL] [Abstract][Full Text] [Related]
19. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist.
Fukushima-Shintani M; Suzuki K; Iwatsuki Y; Abe M; Sugasawa K; Hirayama F; Kawasaki T; Nakahata T
Eur J Haematol; 2009 Apr; 82(4):247-54. PubMed ID: 19183407
[TBL] [Abstract][Full Text] [Related]
20. Role of thrombopoietin in mast cell differentiation.
Migliaccio AR; Rana RA; Vannucchi AM; Manzoli FA
Ann N Y Acad Sci; 2007 Jun; 1106():152-74. PubMed ID: 17468237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
